Prostatic Artery Embolisation: Do We Still Need It and for Whom?

Eur Urol Focus. 2022 Mar;8(2):384-387. doi: 10.1016/j.euf.2022.04.005. Epub 2022 Apr 26.

Abstract

Prostatic artery embolisation (PAE) is now endorsed by international evidence-based guidelines as a treatment for lower urinary tract symptoms presumed secondary to benign prostatic obstruction (LUTS/BPO) for selected patients. PAE is a truly minimally invasive technique, with proven efficacy and safety demonstrated for the short- to mid-term. As it has a unique treatment approach (endovascular instead of transurethral), its profile and ideal application differ clearly from other treatments for LUTS/BPO, which must be considered for patient selection. This mini review examines the role of PAE in the treatment of LUTS/BPO on the basis of current evidence. PATIENT SUMMARY: For properly selected patients, prostatic artery embolisation (PAE), in which arteries feeding the prostate are blocked in a nonsurgical procedure, is one of the treatment options for obstruction of urine outflow caused by benign enlargement of the prostate. This article examines the role of PAE according to the evidence available in the literature.

Keywords: Benign prostatic hyperplasia; Benign prostatic obstruction; Lower urinary tracts symptoms; Minimally invasive treatment; Prostatic artery embolisation.

Publication types

  • Review

MeSH terms

  • Arteries
  • Humans
  • Lower Urinary Tract Symptoms* / complications
  • Lower Urinary Tract Symptoms* / therapy
  • Male
  • Prostate / blood supply
  • Prostatic Hyperplasia* / complications
  • Prostatic Hyperplasia* / diagnosis
  • Prostatic Hyperplasia* / therapy
  • Treatment Outcome